Skip to main content
Erschienen in: Tumor Biology 5/2011

01.10.2011 | Research Article

p53 regulates Ki-67 promoter activity through p53- and Sp1-dependent manner in HeLa cells

verfasst von: Mei-Juan Wang, Dong-Sheng Pei, Guo-Wei Qian, Xiao-Xing Yin, Qian Cheng, Lian-Tao Li, Hui-Zhong Li, Jun-Nian Zheng

Erschienen in: Tumor Biology | Ausgabe 5/2011

Einloggen, um Zugang zu erhalten

Abstract

The expression of the human Ki-67 protein, which is strictly associated with cell proliferation, is regulated by a variety of cellular mediators. In this study, we studied the effects of p53 on Ki-67 promoter in HeLa cells using luciferase reporter assay. The results showed that: (1) p53 inhibited Ki-67 promoter activity in a dose-dependent manner, (2) the p53-binding motifs mediated part of the transcriptional repression of Ki-67 promoter through a sequence-specific interaction with p53, (3) p53 was able to repress the Sp1-stimulated Ki-67 promoter activity, and (4) the Sp1-binding sites were responsible for the p53-mediated transcriptional repression of Ki-67 promoter. In conclusion, p53 inhibited Ki-67 promoter activity via p53- and Sp1-dependent pathways, and the interaction between p53 and Sp1 might be involved in the transcriptional regulatory mechanisms.
Literatur
1.
2.
Zurück zum Zitat Isobe M, Emanuel BS, Givol D, Oren M, Croce CM. Localization of gene for human p53 tumour antigen to band 17p13. Nature. 1986;320:84–5.PubMedCrossRef Isobe M, Emanuel BS, Givol D, Oren M, Croce CM. Localization of gene for human p53 tumour antigen to band 17p13. Nature. 1986;320:84–5.PubMedCrossRef
3.
4.
Zurück zum Zitat Olivier M, Hussain SP, Caron de Fromentel C, Hainaut P, Harris CC. TP53 mutation spectra and load: a tool for generating hypotheses on the etiology of cancer. IARC Sci Publ. 2004;157:247–70.PubMed Olivier M, Hussain SP, Caron de Fromentel C, Hainaut P, Harris CC. TP53 mutation spectra and load: a tool for generating hypotheses on the etiology of cancer. IARC Sci Publ. 2004;157:247–70.PubMed
5.
Zurück zum Zitat Michalovitz D, Halevy O, Oren M. p53 mutations: gains or losses? J Cell Biochem. 1991;45:22–9.PubMedCrossRef Michalovitz D, Halevy O, Oren M. p53 mutations: gains or losses? J Cell Biochem. 1991;45:22–9.PubMedCrossRef
6.
Zurück zum Zitat Scheffenr M, Münger K, Byrne JC, Howley P. The state of the p53 and retinoblastoma genes in human cervical carcinoma cell lines. Proc Natl Acad Sci USA. 1991;88:5523–7.CrossRef Scheffenr M, Münger K, Byrne JC, Howley P. The state of the p53 and retinoblastoma genes in human cervical carcinoma cell lines. Proc Natl Acad Sci USA. 1991;88:5523–7.CrossRef
7.
Zurück zum Zitat Gerdes J, Lemeke H, Baisch H, Wacker HH, Schwab U, Stein H. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the moncelonal antibody ki67. J Immunol. 1984;133:1710–5.PubMed Gerdes J, Lemeke H, Baisch H, Wacker HH, Schwab U, Stein H. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the moncelonal antibody ki67. J Immunol. 1984;133:1710–5.PubMed
8.
Zurück zum Zitat Schlzen T, Gerdes J. The Ki-67 protein:from the known and the unknown. J Cell Physiol. 2000;182:311–22.CrossRef Schlzen T, Gerdes J. The Ki-67 protein:from the known and the unknown. J Cell Physiol. 2000;182:311–22.CrossRef
9.
Zurück zum Zitat Shirendeb U, Hishikawa Y, Moriyama S, Win N, Thu MM, Mar KS, et al. Human papillomavirus infection and its possible correlation with p53 expression in cervical cancer in Japan, Mongolia, and Myanmar. Acta Histochem Cytochem. 2009;42:181–90.PubMedCrossRef Shirendeb U, Hishikawa Y, Moriyama S, Win N, Thu MM, Mar KS, et al. Human papillomavirus infection and its possible correlation with p53 expression in cervical cancer in Japan, Mongolia, and Myanmar. Acta Histochem Cytochem. 2009;42:181–90.PubMedCrossRef
10.
Zurück zum Zitat Gorczyca W, Markiewski M, Kram A. Immunohistochemical analysis of bcl-2 and p53 expression in breast carcinomas: their correlation with Ki-67 growth fraction. Virchows Arch. 1995;426:229–33.PubMedCrossRef Gorczyca W, Markiewski M, Kram A. Immunohistochemical analysis of bcl-2 and p53 expression in breast carcinomas: their correlation with Ki-67 growth fraction. Virchows Arch. 1995;426:229–33.PubMedCrossRef
11.
Zurück zum Zitat Iamaroon A, Khemaleelakul U, Pongsiriwet S, Pintong J. Co-expression of p53 and Ki67 and lack of EBV expression in oral squamous cell carcinoma. J Oral Pathol Med. 2004;33:30–6.PubMedCrossRef Iamaroon A, Khemaleelakul U, Pongsiriwet S, Pintong J. Co-expression of p53 and Ki67 and lack of EBV expression in oral squamous cell carcinoma. J Oral Pathol Med. 2004;33:30–6.PubMedCrossRef
12.
Zurück zum Zitat Georgescu CV, Săftoiu A, Georgescu CC, Ciurea R, Ciurea T. Correlations of proliferation markers, p53 expression and histological findings in colorectal carcinoma. J Gastrointestin Liver Dis. 2007;16:133–9.PubMed Georgescu CV, Săftoiu A, Georgescu CC, Ciurea R, Ciurea T. Correlations of proliferation markers, p53 expression and histological findings in colorectal carcinoma. J Gastrointestin Liver Dis. 2007;16:133–9.PubMed
13.
Zurück zum Zitat Halm U, Tannapfel A, Breitung B, Breidert M, Wittekind CW, Mössner J. Apoptosis and cell proliferation in the metaplasiadysplasia-carcinoma-sequence of Barrett's esophagus. Hepatogastroenterology. 2000;47:962–6.PubMed Halm U, Tannapfel A, Breitung B, Breidert M, Wittekind CW, Mössner J. Apoptosis and cell proliferation in the metaplasiadysplasia-carcinoma-sequence of Barrett's esophagus. Hepatogastroenterology. 2000;47:962–6.PubMed
14.
Zurück zum Zitat Krishnadath KK, Reid BJ, Wang KK. Biomarkers in Barrett esophagus. Mayo Clin Proc. 2001;76:438–46.PubMedCrossRef Krishnadath KK, Reid BJ, Wang KK. Biomarkers in Barrett esophagus. Mayo Clin Proc. 2001;76:438–46.PubMedCrossRef
15.
Zurück zum Zitat Lopes CV, Pereira-Lima J, Hartmann AA. p53 immunohistochemical expression in Barrett's esophagus before and after endoscopic ablation by argon plasma coagulation. Scand J Gastroenterol. 2005;40:259–63.PubMedCrossRef Lopes CV, Pereira-Lima J, Hartmann AA. p53 immunohistochemical expression in Barrett's esophagus before and after endoscopic ablation by argon plasma coagulation. Scand J Gastroenterol. 2005;40:259–63.PubMedCrossRef
16.
Zurück zum Zitat Tian H, Qian GW, Chen FF, Di JH, Zhang BF, Pei DS, et al. A critical role of Sp1 transcription factor in regulating the human Ki-67 gene expression. Tumor Biol. 2010;32:273–83.CrossRef Tian H, Qian GW, Chen FF, Di JH, Zhang BF, Pei DS, et al. A critical role of Sp1 transcription factor in regulating the human Ki-67 gene expression. Tumor Biol. 2010;32:273–83.CrossRef
17.
Zurück zum Zitat Hooghe B, Hulpiau P, Roy FV, Bleser PD. ConTta: a promoter alignment analysis tool for dentification of transcription factor binding sites across species. Nucleic Acids Res. 2008;36:128–32.CrossRef Hooghe B, Hulpiau P, Roy FV, Bleser PD. ConTta: a promoter alignment analysis tool for dentification of transcription factor binding sites across species. Nucleic Acids Res. 2008;36:128–32.CrossRef
18.
Zurück zum Zitat Matlashewski G, Banks L, Pim D, Crawford L. Analysis of human p53 proteins and mRNA levels in normal and transformed cells. Eur J Biochem. 1986;154:665–72.PubMedCrossRef Matlashewski G, Banks L, Pim D, Crawford L. Analysis of human p53 proteins and mRNA levels in normal and transformed cells. Eur J Biochem. 1986;154:665–72.PubMedCrossRef
19.
Zurück zum Zitat Króliczak W, Pietrzak M, Puzianowska-Kuznicka M. p53-dependent suppression of the human cacyclin gene (S100A6) the role of Sp1 and of NFκB. Acta Biochim Pol. 2008;55:559–70.PubMed Króliczak W, Pietrzak M, Puzianowska-Kuznicka M. p53-dependent suppression of the human cacyclin gene (S100A6) the role of Sp1 and of NFκB. Acta Biochim Pol. 2008;55:559–70.PubMed
20.
22.
Zurück zum Zitat Cuesta A, Zambrano A, Royo M, Pascual A. The tumour suppressor p53 regulates the expression of amyloid precursor protein (APP). Biochem J. 2009;418:643–50.PubMedCrossRef Cuesta A, Zambrano A, Royo M, Pascual A. The tumour suppressor p53 regulates the expression of amyloid precursor protein (APP). Biochem J. 2009;418:643–50.PubMedCrossRef
23.
Zurück zum Zitat Shirley SH, Rundhaug JE, Tian J, Cullinan-Ammann N, Lambertz I, Conti CJ, et al. Transcriptional regulation of estrogen receptor-α by p53 in human breast cancer cells. Cancer Res. 2009;69:3404–14.CrossRef Shirley SH, Rundhaug JE, Tian J, Cullinan-Ammann N, Lambertz I, Conti CJ, et al. Transcriptional regulation of estrogen receptor-α by p53 in human breast cancer cells. Cancer Res. 2009;69:3404–14.CrossRef
24.
Zurück zum Zitat Bocangel D, Sengupta S, Mitra S, Bhakat KK. p53-Mediated down-regulation of the human DNA repair gene O6-Methylguanine-DNA Methyltransferase (MGMT) via interaction with Sp1 transcription factor. Anticancer Res. 2009;29:3741–50.PubMed Bocangel D, Sengupta S, Mitra S, Bhakat KK. p53-Mediated down-regulation of the human DNA repair gene O6-Methylguanine-DNA Methyltransferase (MGMT) via interaction with Sp1 transcription factor. Anticancer Res. 2009;29:3741–50.PubMed
25.
Zurück zum Zitat St Clair S, Giono L, Varmeh-Ziaie S, Resnick-Silverman L, Liu WJ, Padi A, et al. DNA damage-induced downregulation of Cdc25C is mediated by p53 via two independent mechanisms: one involves direct binding to the cdc25C promoter. Mol Cell. 2004;16:725–36.PubMedCrossRef St Clair S, Giono L, Varmeh-Ziaie S, Resnick-Silverman L, Liu WJ, Padi A, et al. DNA damage-induced downregulation of Cdc25C is mediated by p53 via two independent mechanisms: one involves direct binding to the cdc25C promoter. Mol Cell. 2004;16:725–36.PubMedCrossRef
26.
Zurück zum Zitat Li B, Lee MY. Transcriptional regulation of the human DNA polymerase δ catalytic subunit gene POLD1 by p53 tumor suppressor and Sp1. J Biol Chem. 2001;276:29729–39.PubMedCrossRef Li B, Lee MY. Transcriptional regulation of the human DNA polymerase δ catalytic subunit gene POLD1 by p53 tumor suppressor and Sp1. J Biol Chem. 2001;276:29729–39.PubMedCrossRef
27.
Zurück zum Zitat Farmer G, Friedlander P, Colgan J, Manley JL, Prives C. Transcriptional repression by p53 involves molecular interactions distinct from those with the TATA box binding protein. Nucleic Acids Res. 1996;24:4281–8.PubMedCrossRef Farmer G, Friedlander P, Colgan J, Manley JL, Prives C. Transcriptional repression by p53 involves molecular interactions distinct from those with the TATA box binding protein. Nucleic Acids Res. 1996;24:4281–8.PubMedCrossRef
28.
Zurück zum Zitat Glait C, Tencer L, Ravid D, Sarfstein R, Liscovitch M, Werner H. Caveolin-1 up-regulates IGF-I receptor gene transcription in breast cancer cells via Sp1- and p53-dependent pathways. Exp Cell Res. 2006;312:3899–908.PubMedCrossRef Glait C, Tencer L, Ravid D, Sarfstein R, Liscovitch M, Werner H. Caveolin-1 up-regulates IGF-I receptor gene transcription in breast cancer cells via Sp1- and p53-dependent pathways. Exp Cell Res. 2006;312:3899–908.PubMedCrossRef
29.
Zurück zum Zitat Farmer G, Colgan J, Nakatani Y, Manley JL, Prives C. Functional interaction between p53, the TATA-binding protein (TBP), and TBP-associated factors in vivo. Mol Cell Biol. 1996;16:4295–304.PubMed Farmer G, Colgan J, Nakatani Y, Manley JL, Prives C. Functional interaction between p53, the TATA-binding protein (TBP), and TBP-associated factors in vivo. Mol Cell Biol. 1996;16:4295–304.PubMed
30.
Zurück zum Zitat Borellini F, Glazer RI. Induction of Sp1-p53 DNA-binding heterocomplexes during granulocyte/macrophage colony-stimulating factor-dependent proliferation in human erythroleukemia cell line TF-1. J Biol Chem. 1993;268:7923–8.PubMed Borellini F, Glazer RI. Induction of Sp1-p53 DNA-binding heterocomplexes during granulocyte/macrophage colony-stimulating factor-dependent proliferation in human erythroleukemia cell line TF-1. J Biol Chem. 1993;268:7923–8.PubMed
31.
Zurück zum Zitat Torgeman A, Mor-Vaknin N, Zelin E, Ben-Aroya Z, Löchelt M, Flügel RM, et al. Sp1-p53 heterocomplex mediates activation of HTLV-I long terminal repeat by 12-O-tetradecanoylphorbol-13-acetate that is antagonized by protein kinase C. Virology. 2001;281:10–20.PubMedCrossRef Torgeman A, Mor-Vaknin N, Zelin E, Ben-Aroya Z, Löchelt M, Flügel RM, et al. Sp1-p53 heterocomplex mediates activation of HTLV-I long terminal repeat by 12-O-tetradecanoylphorbol-13-acetate that is antagonized by protein kinase C. Virology. 2001;281:10–20.PubMedCrossRef
32.
Zurück zum Zitat Koutsodontis G, Vasilaki E, Chou WC, Papakosta P, Kardassis D. Physical and functional interactions between members of the tumour suppressor p53 and the Sp families of transcription factors: importance for the regulation of genes involved in cell-cycle arrest and apoptosis. Biochem J. 2005;389:443–55.PubMedCrossRef Koutsodontis G, Vasilaki E, Chou WC, Papakosta P, Kardassis D. Physical and functional interactions between members of the tumour suppressor p53 and the Sp families of transcription factors: importance for the regulation of genes involved in cell-cycle arrest and apoptosis. Biochem J. 2005;389:443–55.PubMedCrossRef
Metadaten
Titel
p53 regulates Ki-67 promoter activity through p53- and Sp1-dependent manner in HeLa cells
verfasst von
Mei-Juan Wang
Dong-Sheng Pei
Guo-Wei Qian
Xiao-Xing Yin
Qian Cheng
Lian-Tao Li
Hui-Zhong Li
Jun-Nian Zheng
Publikationsdatum
01.10.2011
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 5/2011
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-011-0191-4

Weitere Artikel der Ausgabe 5/2011

Tumor Biology 5/2011 Zur Ausgabe

Alter verschlechtert Prognose bei Endometriumkarzinom

11.05.2024 Endometriumkarzinom Nachrichten

Ein höheres Alter bei der Diagnose eines Endometriumkarzinoms ist mit aggressiveren Tumorcharakteristika assoziiert, scheint aber auch unabhängig von bekannten Risikofaktoren die Prognose der Erkrankung zu verschlimmern.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Erhöhte Mortalität bei postpartalem Brustkrebs

07.05.2024 Mammakarzinom Nachrichten

Auch für Trägerinnen von BRCA-Varianten gilt: Erkranken sie fünf bis zehn Jahre nach der letzten Schwangerschaft an Brustkrebs, ist das Sterberisiko besonders hoch.

Hypertherme Chemotherapie bietet Chance auf Blasenerhalt

07.05.2024 Harnblasenkarzinom Nachrichten

Eine hypertherme intravesikale Chemotherapie mit Mitomycin kann für Patienten mit hochriskantem nicht muskelinvasivem Blasenkrebs eine Alternative zur radikalen Zystektomie darstellen. Kölner Urologen berichten über ihre Erfahrungen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.